In multiple myeloma, some of the BsAb constructs target BCMA (teclistamab, erlanatamab), whereas others target non-BCMA epitopes on plasma cells such as GPRC5D (talquetamab) [47,48,49]. Here, TNFRSF17 is linked to plasma cell myeloma.